- Home
- Companies
- multimmune GmbH
- Products
- multimmune - Model mi-APO - ...
multimmune - Model mi-APO - Apoptosis-Inducing Enzyme
mi-APO is a targeted protein product with potential to be used for the treatment of most tumor types. The product targets surface-bound heat shock protein 70 (Hsp70). Surface-bound Hsp70 is a tumor-specific marker expressed on about 50-75% of various cancer entities, e.g. lung, colon, breast, pancreas. Application of mi-APO, a recombinant serine protease, results in a specific perforin-independent induction of apoptosis in Hsp70-positive tumors and metastases, sparing healthy cells.
Indication: ALL tumors and metastases on which surface-bound Hsp70 is present. mi-APO can be applied in immunosuppressed patients i.e. after radio-chemotherapy.
Market: Given that mi-APO has the potential to be effective against ~50-75% of all tumors, it has the potential to command a substantial market share and incur dramatically lower pipeline development and delivery costs.Status: Proof of principle has been demonstrated in tumor cell lines of various Hsp70 expressing tumor entities, i.e. breast, colon, pancreas, leukaemia (see mi-APO link on right).